Author(s): Bennett JM, Andersen JW, Cassileth PA
Abstract Share this page
Abstract A retrospective analysis of two ECOG adult AML trials conducted from 1976 to 1983 was carried out focusing on long term disease-free survival. This report summarizes the data on 545 patients with a minimum follow up of 7 1/2 years. The complete remission rate was 57\% with an estimated cure rate of 12\%. Of several prognostic variables examined only FAB type M3 (promyelocytic leukemia) was statistically significant (estimated cure rate of 33\% vs 9\% for other FAB subtypes).
This article was published in Leuk Res
and referenced in Journal of Antivirals & Antiretrovirals